Literature DB >> 11544309

The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein.

R A Pierce1, E D Field, T Mutis, T N Golovina, C Von Kap-Herr, M Wilke, J Pool, J Shabanowitz, M J Pettenati, L C Eisenlohr, D F Hunt, E Goulmy, V H Engelhard.   

Abstract

Human minor histocompatibility Ags (mHag) present significant barriers to successful bone marrow transplantation. However, the structure of human mHag and the basis for antigenic disparities are still largely unknown. Here we report the identification of the gene encoding the human mHag HA-2 as a previously unknown member of the class I myosin family, which we have designated MYO1G. The gene is located on the short arm of chromosome 7. Expression of this gene is limited to cells of hemopoietic origin, in keeping with the previously defined tissue expression of the HA-2 Ag. RT-PCR amplification of MYO1G from different individuals led to the identification of two genetic variants, designated MYO1G(V) and MYO1G(M). The former encodes the peptide sequence previously shown to be the HA-2 epitope (YIGEVLVSV), whereas the latter shows a single amino acid change in this peptide (YIGEVLVSM). This change has only a modest effect on peptide binding to the class I MHC-restricted element HLA-A*0201, and a minimal impact on recognition by T cells when added exogenously to target cells. Nonetheless, as detected using either T cells or mass spectrometry, this amino acid change results in a failure of the latter peptide to be presented at the surface of cells that express MYO1G(M) endogenously. These studies have thus identified a new mHag-encoding gene, and thereby provide additional information about both the genetic origins of human mHag as well as the underlying basis of an Ag-positive vs Ag-negative state.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11544309     DOI: 10.4049/jimmunol.167.6.3223

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.

Authors:  Björn de Rijke; Agnes van Horssen-Zoetbrood; Jeffrey M Beekman; Britt Otterud; Frans Maas; Rob Woestenenk; Michel Kester; Mark Leppert; Anton V Schattenberg; Theo de Witte; Elly van de Wiel-van Kemenade; Harry Dolstra
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

2.  The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes.

Authors:  Victor H Engelhard
Journal:  Int J Mass Spectrom       Date:  2007-01-01       Impact factor: 1.986

Review 3.  Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

Authors:  Livius Penter; Catherine J Wu
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 4.  Modular design of immunological synapses and kinapses.

Authors:  Michael L Dustin
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-07       Impact factor: 10.005

5.  CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope.

Authors:  Ania Skowera; Richard J Ellis; Ruben Varela-Calviño; Sefina Arif; Guo Cai Huang; Cassie Van-Krinks; Anna Zaremba; Chloe Rackham; Jennifer S Allen; Timothy I M Tree; Min Zhao; Colin M Dayan; Andrew K Sewell; Wendy W Unger; Wendy Unger; Jan W Drijfhout; Ferry Ossendorp; Bart O Roep; Mark Peakman
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

Review 6.  Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.

Authors:  Marie Bleakley; Cameron J Turtle; Stanley R Riddell
Journal:  Expert Rev Hematol       Date:  2012-08       Impact factor: 2.929

Review 7.  Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.

Authors:  Xin Feng; Kwok Min Hui; Hashem M Younes; Anthony G Brickner
Journal:  Trends Immunol       Date:  2008-10-25       Impact factor: 16.687

8.  Myosin 1G is an abundant class I myosin in lymphocytes whose localization at the plasma membrane depends on its ancient divergent pleckstrin homology (PH) domain (Myo1PH).

Authors:  Genaro Patino-Lopez; L Aravind; Xiaoyun Dong; Michael J Kruhlak; E Michael Ostap; Stephen Shaw
Journal:  J Biol Chem       Date:  2010-01-12       Impact factor: 5.157

9.  Meta-analysis and profiling of cardiac expression modules.

Authors:  Uri David Akavia; Dafna Benayahu
Journal:  Physiol Genomics       Date:  2008-09-09       Impact factor: 3.107

10.  C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.

Authors:  Scott S Tykodi; Nobuharu Fujii; Nathalie Vigneron; Sharon M Lu; Jeffrey K Mito; Maureen X Miranda; Jeffrey Chou; Lilien N Voong; John A Thompson; Brenda M Sandmaier; Peter Cresswell; Benoît Van den Eynde; Stanley R Riddell; Edus H Warren
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.